Table 2.

Characteristics of 25 patients with PIK3CA mutations

Case no.Tumor typeHistologyPIK3CA mutationsOther mutationsResponse (RECIST %)TTP (weeks)a
1OvarianClear cell carcinomac1047BRAF c600PR (−34)17.9+
2OvarianHigh-grade endometrioid carcinomac1047None
3OvarianClear cell carcinomac1049NoneSD (−4)23.3
4OvarianHigh-grade carcinomac542NoneSD (−6)17.9+
5OvarianHigh-grade carcinomac546KRAS c61PR (−34)30.6+
6ColorectalModerately differentiated adenocarcinomac1047KRAS c12PD (+87)7.9
7ColorectalModerately differentiated adenocarcinomac545KRAS c12
8ColorectalModerately differentiated adenocarcinomac1049KRAS c12, c13SD (−2)6.4+
9ColorectalModerately differentiated adenocarcinomac1047KRAS c12
10ColorectalModerately differentiated adenocarcinomac545KRAS c12SD (−3)5.3
11ColorectalModerately differentiated adenocarcinomac545KRAS c12SD (+14)16.1+
12ColorectalModerately differentiated adenocarcinomac545NoneSD (−5)11+
13ColorectalModerately differentiated adenocarcinomac1047NonePDb2.9
14ColorectalModerately differentiated adenocarcinomac545KRAS c61
15EndometrialHigh-grade endometrialc1047NonePR (−37)35.3
16EndometrialEndometrial adenocarcinoma, grade 2c1047NonePR (−60)59+
17EndometrialEndometrial adenocarcinoma, grade 2c1049NonePD (+46)5.6
18BreastLobular carcinoma, ER+, PR+, HER2/neuc1047NonePR (−37)25+
19BreastDuctal carcinoma, grade 2, ER+, PR+, HER2/neuc1047None--
20CervixModerately differentiated squamous cell carcinomac545NoneSD (−4)19.1
21CervixModerately/poorly differentiated squamous cell carcinomac545, c549NonePR (−100)8.9
22Head & NeckPoorly differentiated squamous cell carcinomac1043None
23LungsAdenocarcinomac545None
24PancreasPoorly differentiated adenocarcinomac545KRAS c12
25Small IntestinePoorly differentiated adenocarcinomac1047NonePDb8.1

Abbreviations: TTP, time to progression; ER+, estrogen receptor positive; PR+, progesteron receptor positive; HER2/neu, HER2/neu receptor negative.

  • a+ denotes not progressing at the time of analysis.

  • bClinical progression.